Printer Friendly Version 

Investor Relations Home

ISIS (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$30.14
Change (%) Stock is Down 0.48 (1.57%)
Volume916,844
Data as of 07/25/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
2013 Interactive Annual Report

Recent Press ReleasesMore >>
DateTitle 
07/17/14Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a)
CARLSBAD, Calif., July 17, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.  (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-APO(a)Rx in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.  Patients with high levels of Lp(a) have an increased risk of atherosclerosis, coronary heart disease, aortic stenosis, heart attack and stroke.  ISIS-APO(a)Rx is designed to reduce Lp(a) by inhibiting the production of apolipoprotein(a)... 
Printer Friendly Version
07/16/14Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
CARLSBAD, Calif., July 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).  ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripher... 
Printer Friendly Version
07/02/14Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program
CARLSBAD, Calif., July 2, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million payment from GlaxoSmithKline (GSK) related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV). "Our collaboration with GSK has been very productive resulting in three novel antisense drugs in our pipeline.  We look forward to continuing to advance these drugs and add additional new drugs to our pipeline with GSK,"... 
Printer Friendly Version
06/24/14Isis Pharmaceuticals Earns $1 Million From GSK for Advancing ISIS-TTR Rx
CARLSBAD, Calif., June 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).  ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripher... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
08/24/14
through
08/28/14
XXI International Round Table on Nucleosides, Nucleotides and Nucleic Acids
LocationPoznan, Poland
Primary IR Contact
D. Wade Walke, Ph.D.
Vice President, Corporate Communications and Investor Relations
Isis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010
Phone: 760-603-2331

For more information requests, please visit our Information Request page.

If you are interested in Isis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Online Investor Kit

Quickly download files right from our Investor Relations Web site.

Learn More

Financial Tearsheet

Download a brief overview of Isis.

Learn More

News Feeds

Get the latest.

Subscribe

Receive Isis alerts in your email.

Sign Up